Processing

Please wait...

Settings

Settings

Goto Application

1. WO2020141452 - ANTI-FAMILY WITH SEQUENCE SIMILARITY 19, MEMBER A5 ANTIBODIES AND METHOD OF USE THEREOF

Publication Number WO/2020/141452
Publication Date 09.07.2020
International Application No. PCT/IB2019/061461
International Filing Date 31.12.2019
IPC
C07K 16/24 2006.01
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
18against material from animals or humans
24against cytokines, lymphokines or interferons
A61K 39/00 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
CPC
C07K 16/24
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
18against material from animals or humans
24against cytokines, lymphokines or interferons
C07K 2317/24
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
2317Immunoglobulins specific features
20characterized by taxonomic origin
24containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
C07K 2317/34
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
2317Immunoglobulins specific features
30characterized by aspects of specificity or valency
34Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
C07K 2317/565
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
2317Immunoglobulins specific features
50characterized by immunoglobulin fragments
56variable (Fv) region, i.e. VH and/or VL
565Complementarity determining region [CDR]
C07K 2317/567
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
2317Immunoglobulins specific features
50characterized by immunoglobulin fragments
56variable (Fv) region, i.e. VH and/or VL
567Framework region [FR]
C07K 2317/622
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
2317Immunoglobulins specific features
60characterized by non-natural combinations of immunoglobulin fragments
62comprising only variable region components
622Single chain antibody (scFv)
Applicants
  • NEURACLE SCIENCE CO., LTD. [KR]/[KR]
Inventors
  • KIM, Bongcheol
  • KIM, Wonkyum
  • KIM, Dong Sik
  • LEE, Jae-Keun
  • YOON, Jeongwon
  • CHUNG, Junho
  • JIN, Junyeong
Priority Data
62/787,71102.01.2019US
62/838,19024.04.2019US
Publication Language English (EN)
Filing Language English (EN)
Designated States
Title
(EN) ANTI-FAMILY WITH SEQUENCE SIMILARITY 19, MEMBER A5 ANTIBODIES AND METHOD OF USE THEREOF
(FR) ANTICORPS ANTI-FAMILLE À SIMILARITÉ DE SÉQUENCE 19, MEMBRE A5 ET LEUR PROCÉDÉ D'UTILISATION
Abstract
(EN)
The present disclosure provides antibodies that specifically bind to human FAM19A5 and compositions comprising such antibodies. In some embodiments, antibodies are de-immunized to reduce immunogenicity in a human subject. In certain embodiments, antibodies have undergone affinity maturation. In some embodiments, the anti-FAM19A5 antibodies can modulate FAM19A5 activity, e.g, inhibit, suppress, reduce, or reverse the onset of reactive gliosis and/or excessive proliferation of reactive astrocytes, utilizing such antibodies. The present disclosure also provides methods for treating disorders, such as central nervous system damage, a degenerative brain disorder, a neuropathic pain, or a cancer, by administering an antibody that specifically binds to human FAM19A5.
(FR)
La présente invention concerne des anticorps qui se lient de manière spécifique au FAM19A5 humain et des compositions comprenant de tels anticorps. Selon certains modes de réalisation, les anticorps sont désimmunisés pour réduire l'immunogénicité chez un sujet humain. Selon certains modes de réalisation, les anticorps ont subi une maturation d'affinité. Selon certains modes de réalisation, les anticorps anti-FAM19A5 peuvent moduler l'activité de FAM19A5, par exemple, inhiber, supprimer, réduire ou inverser l'apparition d'une gliose réactive et/ou d'une prolifération excessive d'astrocytes réactifs, à l'aide de tels anticorps. La présente invention concerne également des méthodes de traitement de troubles, tels que des lésions du système nerveux central, un trouble cérébral dégénératif, une douleur neuropathique, ou un cancer, par administration d'un anticorps se liant de manière spécifique au FAM19A5 humain.
Latest bibliographic data on file with the International Bureau